Why Sharing Clinical Trial Experiences Can Harm Research
By: Lauren Schmitt, PhD, Chief Science Officer, PMSFDate: December 22, 2025 How Families Can Help Protect the Path to New Treatments…
Driving Research Breakthroughs
Driving Research Breakthroughs Funding research, treatments, and cures for Phelan-McDermid SyndromeThe Phelan-McDermid Syndrome Foundation is proud to launch Driving Research Breakthroughs,…
2025 Shannon O’Boyle Memorial Grant Awardee
We have exciting news to share with our Phelan-McDermid syndrome community! This year’s PMSF research grant will help drive groundbreaking science…
PYC Therapeutics Update – Progress on RNA-Based Therapy for Phelan-McDermid Syndrome
The Phelan-McDermid Syndrome Foundation is committed to keeping our community informed about the latest scientific and medical research, including progress in…
Bridging Science and Hope: Updates on the 2024 PMSF Research Grants
By Meagan HutchinsonIn 2024, the Phelan-McDermid Syndrome Foundation awarded three research grants aimed not only at funding discovery but also changing…
Passport to Progress: Diane Joins Conference in Barcelona for a New Era of PMSF and Our Global Community
By Diane Linnehan, COO & Interim CEO, PMSFDiane Linnehan, the Chief Operating Officer and co-interim Chief Executive Officer of the Phelan-McDermid…
“Mini-Brains” and SHANK3—A New Way to Study Phelan-McDermid Syndrome in the Lab
By Meagan Hutchinson Click here to read the full publication Summary: Many parts of brain development are difficult for scientists to…
Conference Updates from Dr. Lauren
Earlier this spring, Dr. Lauren traveled to the Gatlinburg Conference in San Diego, CA, and the International Society for Autism Research…
Diagnosing the Undiagnosed: PMSF Partnering with BioLogic Pharma Solutions to Help Improve SHANK3 Testing
https://www.healthshots.com/brand-stories/biologic-calls-for-better-genetic-testing-at-acmg-2025/BioLogic Pharma Solutions, in partnership with Neuren Pharmaceuticals, has been on the conference tour this spring to share their research revealing…
Class I vs. Class II Deletions: What’s the Difference?
In Phelan-McDermid syndrome, you are likely familiar with the terminology and differences between SHANK3 deletions, SHANK3 variations, and even ring chromosomes.…